Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes

(2011) Alexandra Rogue et al.   PLoS One

1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists

(2010) Jiwon Choi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

New Insights on the Mechanism of PPAR-targeted Drugs

(2010) Uwe Grether et al.   ChemMedChem

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes

(2010) Fredrick L. Dunn et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5

(2010) Jang Hyun Choi et al.   NATURE

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

(2009) Agnes Bénardeau et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Thiazolidinediones and Congestive Heart Failure

(2009) Rujul R. Patel   Cardiology in Review

Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists

(2009) Uwe Grether et al.   ChemMedChem

INT131: A Selective Modulator of PPARγ

(2009) Alykhan Motani et al.   JOURNAL OF MOLECULAR BIOLOGY

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

(2009) Robert R Henry et al.   LANCET

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION